RETIMIX2020-04-01T12:17:27+02:00

Products – RETIMIX®

CURCUMA-PHYPHOLIPID 250 mg

BOSWELLIA-PHYPHOLIPID 250 mg

RETIMIX® is a food supplement with an innovative formula (Casperiva®) based on Turmeric (Curcuma longa) and Indian oli-banum (Boswellia serrata) complexed within phytosomes.

GLUTEN FREE

SUGAR FREE

BUY PRODUCT

The patented technology of Eye Pharma

INGREDIENTS

Casperiva®, a concentrated blend of synergistic active ingredients: curcuminoids and boswelic acids. Our patented system (Phytosome®) allows greater bioavailability of these active compounds.

DETAILS

Extracts of curcuminoid active ingredients (curcumin, demethoxicurcumin and bisdemethoxicurcumin) and boswellic acids belonging to the triterpenoid family, including AKBA (3-Acetyl-11-keto-beta-Boswellic Acid), the most well documented and active compound.
Curcuminoids and boswelic acids (AKBA) act synergistically to target chronic inflammation and pathogenic neoangiogenesis.
The specific characteristics of these active ingredients make them an ideal treatment to support drug therapies for eye inflammatory diseases with formation of new vessels.

INNOVATION

The combination of curcuminoids and boswelic acids in Casperiva® allows their synergistic action to control the inflammatory response on several levels.

Casperiva® is an Eye Pharma SpA brand
Phytosome® is an Indena SpA brand

TECNOLOGY

INTERVIEWS

NEWS AND INSIGHTS

WET AGE-RELATED MACULAR DEGENERATION (AMD): PHARMACOLOGICAL THERAPIES (INTRAVITREAL INJECTIONS)

Intravitreal injections, performed by a qualified ophthalmologist, allow placing a specific drug directly into the space in the back of the eye called the vitreous cavity, near the retina …

Read more
Le informazioni, immagini, descrizioni e quanto altro riportato nel sito relativi a dispositivi medici non sono di natura pubblicitaria ma materiale informativo rivolto esclusivamente a Professionisti dell’area sanitaria. Pertanto proseguendo nella navigazione l’utente dichiara di essere un Professionista dell’area sanitaria. Riferimento:Ministero della Salute – “Nuove linee guida della pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici” del 28 Marzo 2013; Aggiornamento delle “Linee guida in merito all’utilizzo di nuovi mezzi di diffusione della pubblicità sanitaria” del 17 Febbraio 2010 - These statements have not been evaluated by the Food & Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Please contact your healthcare professional immediately if you experience any unwanted side effects. The information contained herein is for informational purposes only and does not establish a doctor-patient relationship. Please be sure to consult your physician before taking this or any other product. Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.